Drug-resistant tuberculous meningitis

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 6, 2013, Pages 605-621

  Garg, Ravindra K ^a   Jain, Amita ^a   Malhotra, Hardeep S ^a   Agrawal, Avinash ^a   Garg, Rajiv ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

antituberculosis drugs; drug resistance; drug susceptibility testing; meningitis; Mycobacterium tuberculosis; tuberculosis; Xpert MTB RIF assay

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DEXAMETHASONE; ETHAMBUTOL; ETHIONAMIDE; IMIPENEM; INFLIXIMAB; ISONIAZID; KANAMYCIN; KATG PROTEIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PLACEBO; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; STREPTOMYCIN; TERIZIDONE; THALIDOMIDE; THIOACETAZONE; UNINDEXED DRUG;

ADD ON THERAPY; ANTIBIOTIC SENSITIVITY; ASSAY; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; CEREBROSPINAL FLUID EXAMINATION; CLINICAL FEATURE; DRUG MEGADOSE; DRUG PENETRATION; DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; NEUROIMAGING; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PUBLIC HEALTH PROBLEM; REVIEW; SENSITIVITY AND SPECIFICITY; TUBERCULOUS MENINGITIS;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CATALASE; CHILD; COINFECTION; HIV INFECTIONS; HUMANS; ISONIAZID; MUTATION; MYCOBACTERIUM TUBERCULOSIS; SURVIVAL ANALYSIS; TUBERCULOSIS, MENINGEAL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84878887078     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.13.39     Document Type: Review

References (84)

1. Zumla A, Abubakar I, Raviglione M et al. Drug-resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs. J. Infect. Dis. 205(Suppl. 2), S228-S240 (2012).
2. Nathanson E, Nunn P, Uplekar M et al. MDR tuberculosis-critical steps for prevention and control. N. Engl. J. Med. 363(11), 1050-1058 (2010).
3. Rock RB, Olin M, Baker CA, Molitor TW, Peterson PK. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin. Microbiol. Rev. 21(2), 243-261; table of contents (2008).
4. The Lancet Neurology. Tuberculosis of the CNS remains a lethal threat. Lancet Neurol. 10, 395 (2011).
5. Garg RK. Tuberculous meningitis. Acta Neurol. Scand. 122(2), 75-90 (2010).
6. Byrd TF, Davis LE. Multidrug-resistant tuberculous meningitis. Curr. Neurol. Neurosci. Rep. 7(6), 470-475 (2007).
7. Ho Dang Trung N, Le Thi Phuong T, Wolbers M et al.; VIZIONS CNS Infection Network. Aetiologies of central nervous system infection in Viet Nam: a prospective provincial hospital-based descriptive surveillance study. PLoS ONE 7(5), e37825 (2012).
8. Marais S, Pepper DJ, Schutz C, Wilkinson RJ, Meintjes G. Presentation and outcome of tuberculous meningitis in a high HIV prevalence setting. PLoS ONE 6(5), e20077 (2011).
9. Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin. Infect. Dis. 49(9), 1350-1357 (2009).
10. Vinnard C, Winston CA, Wileyto EP, MacGregor RR, Bisson GP. Multidrug resistant tuberculous meningitis in the United States, 1993-2005. J. Infect. 63(3), 240-242 (2011).
11. Vinnard C, Winston CA, Wileyto EP, MacGregor RR, Bisson GP. Isoniazidresistant tuberculous meningitis, United States, 1993-2005. Emerging Infect. Dis. 17(3), 539-542 (2011).
12. Nagarathna S, Rafi W, Veenakumari HB, Mani R, Satishchandra P, Chandramuki A. Drug susceptibility profiling of tuberculous meningitis. Int. J. Tuberc. Lung Dis. 12(1), 105-107 (2008).
13. Caws M, Thwaites GE, Duy PM et al. Molecular analysis of Mycobacterium tuberculosis causing multidrug-resistant tuberculosis meningitis. Int. J. Tuberc. Lung Dis. 11(2), 202-208 (2007).
14. Duo L, Ying B, Song X et al. Molecular profile of drug resistance in tuberculous meningitis from southwest China. Clin. Infect. Dis. 53(11), 1067-1073 (2011).
15. Patel VB, Padayatchi N, Bhigjee AI et al. Multidrug-resistant tuberculous meningitis in Kwa Zulu-Natal, South Africa. Clin. Infect. Dis. 38(6), 851-856 (2004).
16. Croda MG, Vidal JE, Hernández AV, Dal Molin T, Gualberto FA, de Oliveira AC. Tuberculous meningitis in HIV-infected patients in Brazil: clinical and laboratory characteristics and factors associated with mortality. Int. J. Infect. Dis. 14(7), e586-e591 (2010).
17. Torok ME, Chau TT, Mai PP et al. Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PLoS ONE 3(3), e1772 (2008).
18. Müller B, Streicher EM, Hoek KG et al. inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa? Int. J. Tuberc. Lung Dis. 15(3), 344-351 (2011).
19. Schaaf HS, Victor TC, Venter A et al. Ethionamide cross-and co-resistance in children with isoniazid-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 13(11), 1355-1359 (2009).
20. Faksri K, Drobniewski F, Nikolayevskyy V et al. Epidemiological trends and clinical comparisons of Mycobacterium tuberculosis lineages in Thai TB meningitis. Tuberculosis (Edinb.) 91(6), 594-600 (2011).
21. Tho DQ, Török ME, Yen NT et al. Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis. Antimicrob. Agents Chemother. 56(6), 3074-3079 (2012).
22. Parwati I, van Crevel R, van Soolingen D. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect. Dis. 10(2), 103-111 (2010).
23. Velez DR, Wejse C, Stryjewski ME et al. Variants in Toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans. Hum. Genet. 127(1), 65-73 (2010).
24. Shah JA, Vary JC, Chau TT et al. Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis. J. Immunol. 189(4), 1737-1746 (2012).
25. Horne DJ, Randhawa AK, Chau TT et al. Common polymorphisms in the PKP3-SIGIRR-TMEM16J gene region are associated with susceptibility to tuberculosis. J. Infect. Dis. 205(4), 586-594 (2012).
26. Hawn TR, Dunstan SJ, Thwaites GE et al. A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J. Infect. Dis. 194(8), 1127-1134 (2006).
27. Thuong NT, Hawn TR, Thwaites GE et al. A polymorphism in human TLR2 is associated with increased susceptibility to tuberculous meningitis. Genes Immun. 8(5), 422-428 (2007).
28. Thuong NT, Dunstan SJ, Chau TT et al. Identification of tuberculosis susceptibility genes with human macrophage gene expression profiles. PLoS Pathog. 4(12), e1000229 (2008).
29. Misra UK, Kalita J, Maurya PK. Stroke in tuberculous meningitis. J. Neurol. Sci. 303(1-2), 22-30 (2011).
30. Thwaites GE, Lan NT, Dung NH et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J. Infect. Dis. 192(1), 79-88 (2005).
31. Daikos GL, Cleary T, Rodriguez A, Fischl MA. Multidrug-resistant tuberculous meningitis in patients with AIDS. Int. J. Tuberc. Lung Dis. 7(4), 394-398 (2003).
32. Marais S, Thwaites G, Schoeman JF et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect. Dis. 10(11), 803-812 (2010).
33. Panicker JN, Nagaraja D, Subbakrishna DK, Venkataswamy MM, Chandramuki A. Role of the BACTEC radiometric method in the evaluation of patients with clinically probable tuberculous meningitis. Ann. Indian Acad. Neurol. 13(2), 128-131 (2010).
34. Sankar S, Ramamurthy M, Nandagopal B, Sridharan G. An appraisal of PCR-based technology in the detection of Mycobacterium tuberculosis. Mol. Diagn. Ther. 15(1), 1-11 (2011).
35. Takahashi T, Tamura M, Takasu T. The PCR-based diagnosis of central nervous system tuberculosis: up to date. Tuberc. Res. Treat. 2012, 831292 (2012).
36. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM Jr. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect. Dis. 3(10), 633-643 (2003).
37. Thakur R, Goyal R, Sarma S. Laboratory diagnosis of tuberculous meningitis-is there a scope for further improvement? J. Lab. Physicians 2(1), 21-24 (2010).
38. Thwaites GE, Caws M, Chau TT et al. Comparison of conventional bacteriology with nucleic acid amplification (amplified mycobacterium direct test) for diagnosis of tuberculous meningitis before and after inception of antituberculosis chemotherapy. J. Clin. Microbiol. 42(3), 996-1002 (2004).
39. Huang HJ, Xiang DR, Sheng JF et al. rpoB nested PCR and sequencing for the early diagnosis of tuberculous meningitis and rifampicin resistance. Int. J. Tuberc. Lung Dis. 13(6), 749-754 (2009).
40. Alvarez-Uria G, Azcona JM, Midde M, Naik PK, Reddy S, Reddy R. Rapid diagnosis of pulmonary and extrapulmonary tuberculosis in HIV-infected patients. Comparison of LED fluorescent microscopy and the GeneXpert MTB/RIF assay in a district hospital in India. Tuberc. Res. Treat. 2012, 932862 (2012).
41. Singh B, Garg RK, Singh MK et al. Computed tomography angiography in patients with tuberculous meningitis. J. Infect. 64(6), 565-572 (2012).
42. Gupta RK, Kumar S. Central nervous system tuberculosis. Neuroimaging Clin. N. Am. 21(4), 795-814, vii (2011).
43. Brancusi F, Farrar J, Heemskerk D. Tuberculous meningitis in adults: a review of a decade of developments focusing on prognostic factors for outcome. Future Microbiol. 7(9), 1101-1116 (2012).
44. Padayatchi N, Bamber S, Dawood H, Bobat R. Multidrug-resistant tuberculous meningitis in children in Durban, South Africa. Pediatr. Infect. Dis. J. 25(2), 147-150 (2006). First published information on drugresistant tuberculous meningitis in children.
45. Cheng SL, Wang HC, Yang PC. Paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 11(12), 1290-1295 (2007).
46. Sinha MK, Garg RK, Anuradha HK, Agarwal A, Parihar A, Mandhani PA. Paradoxical vision loss associated with optochiasmatic tuberculoma in tuberculous meningitis: a report of 8 patients. J. Infect. 60(6), 458-466 (2010).
47. Nicolls DJ, King M, Holland D, Bala J, del Rio C. Intracranial tuberculomas developing while on therapy for pulmonary tuberculosis. Lancet Infect. Dis. 5(12), 795-801 (2005).
48. Pepper DJ, Marais S, Maartens G et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin. Infect. Dis. 48(11), e96-e107 (2009).
49. Marais S, Meintjes G, Pepper DJ et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin. Infect. Dis. 56(3), 450-460 (2013).
50. Marx GE, Chan ED. Tuberculous meningitis: diagnosis and treatment overview. Tuberc. Res. Treat. 2011, 798764 (2011).
51. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb). 90(5), 279-292 (2010).
52. Thwaites GE, Bhavnani SM, Chau TT et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob. Agents Chemother. 55(7), 3244-3253 (2011).
53. Ruslami R, Ganiem AR, Dian S et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled Phase 2 trial. Lancet Infect. Dis. 13(1), 27-35 (2013).
54. Menzies D, Benedetti A, Paydar A et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 6(9), e1000150 (2009).
55. Seddon JA, Visser DH, Bartens M et al. Impact of drug resistance on clinical outcome in children with tuberculous meningitis. Pediatr. Infect. Dis. J. 31(7), 711-716 (2012).
56. Thwaites GE, Nguyen DB, Nguyen HD et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med. 351(17), 1741-1751 (2004).
57. Török ME, Nguyen DB, Tran TH et al. Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS ONE 6(12), e27821 (2011).
58. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics 99(2), 226-231 (1997).
59. Uhlin M, Andersson J, Zumla A, Maeurer M. Adjunct immunotherapies for tuberculosis. J. Infect. Dis. 205(Suppl. 2), S325-S334 (2012).
60. Schoeman JF, Andronikou S, Stefan DC, Freeman N, van Toorn R. Tuberculous meningitis-related optic neuritis: recovery of vision with thalidomide in 4 consecutive cases. J. Child Neurol. 25(7), 822-828 (2010).
61. Schoeman JF, Springer P, van Rensburg AJ et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J. Child Neurol. 19(4), 250-257 (2004).
62. Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin. Infect. Dis. 47(10), e83-e85 (2008).
63. Lee JY, Yim JJ, Yoon BW. Adjuvant interferon-? treatment in two cases of refractory tuberculosis of the brain. Clin. Neurol. Neurosurg. 114(6), 732-734 (2012).
64. Falzon D, Jaramillo E, Schünemann HJ et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur. Respir. J. 38(3), 516-528 (2011).
65. Lawn SD, Török ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr. Opin. Infect. Dis. 24(1), 34-42 (2011).
66. Lawn SD, Wood R. Poor prognosis of HIV-associated tuberculous meningitis regardless of the timing of antiretroviral therapy. Clin. Infect. Dis. 52(11), 1384-1387 (2011).
67. Rajshekhar V. Management of hydrocephalus in patients with tuberculous meningitis. Neurol. India 57(4), 368-374 (2009).
68. Clemente Morgado T, Kinsky M, Carrara H, Rothemeyer S, Semple P. Prognostic value of computed tomographyevident cerebral infarcts in adult patients with tuberculous meningitis and hydrocephalus treated with an external ventricular drain. World Neurosurg. doi:10.1016/j.wneu.2012.09.021 (2012) (Epub ahead of print).
69. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis. 10(9), 621-629 (2010).
70. Dhasmana DJ, Davidson RN. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with tuberculous meningitis. J. Infect Dis. 192(12), 2134-2141 (2005).
71. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin. Infect. Dis. 53(4), 369-372 (2011).
72. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367(9517), 1173-1180 (2006).
73. Suthar AB, Lawn SD, del Amo J et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 9(7), e1001270 (2012).
74. Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV, Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS 26(17), 2121-2133 (2012).
75. Abu-Raddad LJ, Sabatelli L, Achterberg JT et al. Epidemiological benefits of moreeffective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl Acad. Sci. USA 106(33), 13980-13985 (2009).
76. Yan M, Ma S. Recent advances in the research of heterocyclic compounds as antitubercular agents. ChemMedChem 7(12), 2063-2075 (2012).
77. Chaisson RE, Nuermberger EL. Confronting multidrug-resistant tuberculosis. N. Engl. J. Med. 366(23), 2223-2224 (2012).
78. Sofia M, Maniscalco M, Honoré N et al. Familial outbreak of disseminated multidrug-resistant tuberculosis and meningitis. Int. J. Tuberc. Lung Dis. 5(6), 551-558 (2001).
79. Caws M, Thwaites G, Stepniewska K et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with human immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. J. Clin. Microbiol. 44(11), 3934-3939 (2006).
80. Cecchini D, Ambrosioni J, Brezzo C et al. Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome. AIDS 21(3), 373-374 (2007).
81. Venkataswamy MM, Rafi W, Nagarathna S, Ravi V, Chandramuki A. Comparative evaluation of BACTEC 460TB system and Lowenstein-Jensen medium for the isolation of M. tuberculosis from cerebrospinal fluid samples of tuberculous meningitis patients. Indian J. Med. Microbiol. 25(3), 236-240 (2007).
82. Baveja CP, Gumma V, Jain M, Chaudhary M, Talukdar B, Sharma VK. Multi drug resistant tuberculous meningitis in pediatric age group. Iranian J. Pediatr. 18, 309-314 (2008).
83. Vinnard C, Winston CA, Wileyto EP, Macgregor RR, Bisson GP. Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study. BMJ 341, c4451 (2010).
84. Jain A, Dixit P, Jaiswal I, Garg RK, Kumar R. Drug resistance in mycobacterial isolates from meningitis cases. Pediatr. Infect. Dis. J. 31(12), 1317 (2012).